CONDENSED COMBINED AND CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (60,105)	$ (38,766)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	754	389
Stock-based compensation expense	8,859	3,131
Write-down of inventory	0	19
Payments received on net investment in lease	6	7
Changes in assets and liabilities:
Accounts receivable	(2,149)	(766)
Unbilled receivables	(1,384)	(48)
Inventory	308	(1,064)
Prepaid expenses and other current assets	(439)	(2,909)
Due from related parties	14	1,452
Other assets - related party		158
Other long term assets	62	(614)
Accounts payable	(1,522)	3,923
Deferred grant funding	(1,403)	1,857
Deferred revenue	1,098	956
Due to related parties	(1,920)	1,198
Accrued expenses and other current liabilities	827	2,030
Net cash used in operating activities	(56,994)	(29,047)
Cash flows from investing activities:
Purchases of property and equipment	(427)	(1,736)
Net cash used in investing activities	(427)	(1,736)
Cash flows from financing activities:
Proceeds from exercise of stock options	2	1,462
Proceeds from issuance of Series D convertible preferred stock		30,468
Stock issuance costs related to Series D convertible preferred stock		(7)
Investment from 4Bionics, LLC		3,516
Net cash provided by financing activities	2	35,439
Net (decrease) increase in cash and cash equivalents and restricted cash	(57,419)	4,656
Cash, cash equivalents and restricted cash, beginning of period	191,160	64,286
Cash, cash equivalents and restricted cash, end of period	133,741	68,942
Reconciliation of cash, cash equivalents, and restricted cash reported in the balance sheets
Cash and cash equivalents	132,482	65,475
Restricted cash	1,259	3,467
Total cash, cash equivalents and restricted cash	133,741	68,942
Supplemental disclosure of cash flow information:
Cash received from exchange of research and development tax credits		$ 324
Supplemental disclosure of noncash information:
Write-off of notes receivable	$ 90